Literature DB >> 1981713

Covalent binding of zomepirac glucuronide to proteins: evidence for a Schiff base mechanism.

P C Smith1, L Z Benet, A F McDonagh.   

Abstract

Carboxylic acids can undergo irreversible binding to proteins via their acyl glucuronide metabolites. Such binding occurs in humans and in vitro for bilirubin and the anti-inflammatory drugs zomepirac and tolmetin and may have toxicological significance. The mechanism of the binding is uncertain, but is thought to involve nucleophilic displacement of glucuronic acid by free cysteine thiols, tyrosine, or lysine residues of the protein. We now present evidence, using zomepirac glucuronide, for an alternative mechanism where irreversible binding occurs by isomerization of the glucuronide and formation of an imine linkage between the glucuronic acid moiety of the conjugate and a lysine or terminal amino group of the protein. Involvement of a protein thiol in the binding mechanism was ruled out by experiments with the thiol blocking agent, p-hydroxymercuribenzoate. Moreover, significant irreversible binding occurred when the cysteine free protein, alpha s1-casein, was incubated in solution with zomepirac glucuronide in vitro. When zomepirac glucuronide was added to solutions with albumin in the presence of the imine trapping reagent, sodium cyanide, or the reducing agent, sodium cyanoborohydride, irreversible binding of zomepirac increased 8.3- and 5.5-fold relative to controls, respectively, after 6 hr at 37 degrees C. The product formed after treatment of solutions of zomepirac glucuronide and albumin with sodium cyanoborohydride was stable in dilute acid, whereas similar acid treatment of zomepirac-albumin adduct from control incubations, obtained after sodium cyanide exposure, released 30% of the total adduct. Only isomeric conjugates of zomepirac glucuronide were released from zomepirac-albumin adduct by mild acid; no beta 1-isomer was detected.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1981713

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  Reaction of acyl glucuronides with insulin in vitro: identification of an imine mechanism by electrospray ionization mass spectrometry.

Authors:  J H Liu; C D Marquez; S T Weintraub; P C Smith
Journal:  Pharm Res       Date:  1998-02       Impact factor: 4.200

2.  Mass spectrometric characterization of circulating covalent protein adducts derived from a drug acyl glucuronide metabolite: multiple albumin adductions in diclofenac patients.

Authors:  Thomas G Hammond; Xiaoli Meng; Rosalind E Jenkins; James L Maggs; Anahi Santoyo Castelazo; Sophie L Regan; Stuart N L Bennett; Caroline J Earnshaw; Guruprasad P Aithal; Ira Pande; J Gerry Kenna; Andrew V Stachulski; B Kevin Park; Dominic P Williams
Journal:  J Pharmacol Exp Ther       Date:  2014-06-05       Impact factor: 4.030

3.  Evidence for covalent binding of acyl glucuronides to serum albumin via an imine mechanism as revealed by tandem mass spectrometry.

Authors:  A Ding; J C Ojingwa; A F McDonagh; A L Burlingame; L Z Benet
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

4.  Glucuronidation and covalent protein binding of benoxaprofen and flunoxaprofen in sandwich-cultured rat and human hepatocytes.

Authors:  Jennifer Q Dong; Philip C Smith
Journal:  Drug Metab Dispos       Date:  2009-09-22       Impact factor: 3.922

Review 5.  Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors.

Authors:  H K Kroemer; U Klotz
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

6.  An enzyme-linked immunosorbent assay for detecting 3-phenoxybenzoic acid in plasma and its application in farmers and consumers.

Authors:  Sarunya Thiphom; Tippawan Prapamontol; Somporn Chantara; Ampica Mangklabruks; Chaisuree Suphavilai; Ki Chang Ahn; Shirley J Gee; Bruce D Hammock
Journal:  Anal Methods       Date:  2012-10-24       Impact factor: 2.896

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.